Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

Rhea-AI Summary

Vallon Pharmaceuticals (NASDAQ: VLON) announced that CEO David Baker will present at the Virtual Investor 2022 Top Picks Conference on January 25, 2022, at 9:00 AM ET. The event will include a presentation, moderated discussion, and interactive Q&A, allowing investors to submit questions live or in advance. A live webcast will be available, with a replay accessible post-event.

– Live video webcast presentation on Tuesday, January 25^th at 9:00 AM ET

PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that David Baker, President and Chief Executive Officer will present at the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 9:00 AM ET.

As part of the virtual event, the Company will provide a brief presentation, followed by a moderated discussion and an interactive Q&A session. In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com. The Company will answer as many questions as possible during the event.

A live video webcast of the event will be available on the Events page of the Investors section of the Company’s website (vallon-pharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Vallon Pharmaceuticals, Inc.

Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with CNS disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse-deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

For more information about the company, please visit www.vallon-pharma.com or connect with us on LinkedIn or Twitter.

References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com

FAQ

What is the date and time of Vallon Pharmaceuticals' presentation at the Virtual Investor 2022 Top Picks Conference?

Vallon Pharmaceuticals will present on January 25, 2022, at 9:00 AM ET.

Who will present for Vallon Pharmaceuticals at the conference?

David Baker, President and CEO, will be the presenter for Vallon Pharmaceuticals.

How can I access the live webcast of the Vallon Pharmaceuticals presentation?

The live webcast can be accessed via the Events page on Vallon Pharmaceuticals' website.

Will there be a Q&A session during Vallon Pharmaceuticals' presentation?

Yes, there will be a moderated Q&A session where investors can submit questions.

How long will the replay of the Vallon Pharmaceuticals presentation be available?

The replay of the presentation will be available for 90 days after the live event.